Expression of bcl-2 and p53 in Merkel cell carcinoma: An immunohistochemical study

American Journal of Dermatopathology

Volumn 18, Issue 3, 1996, Pages 273-277

  Kennedy, M M ^a,b   Blessing, Karen ^a   King, George ^a   Kerr, Keith M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Apoptosis; Bcl 2; Immunohistochemistry; Merkel cell carcinoma; p53; Prognosis

Indexed keywords

GENE PRODUCT; ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; MERKEL CELL TUMOR; PRIORITY JOURNAL; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

AGED; AGED, 80 AND OVER; APOPTOSIS; CARCINOMA, MERKEL CELL; COLORING AGENTS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029902064     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000372-199606000-00006     Document Type: Article

References (25)

1. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83:5214-8.
2. Vaux DL, Cory S. Adams JM. Bcl-2 gene promotes haemopoietic cell survival and co-operates with c-myc to immortalize pre-B cells. Nature 1988;335:440-2.
3. Hockenberry D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-36.
4. Pezzella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990;137:225-32.
5. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. Bcl-2 in normal human breast and carcinoma: association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in-situ cancer. Br J Cancer 1994;69:135-9.
6. Pilotti S, Collini P, Rilke F, Cattoretti G, Del Bo R, Pierotti MA. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994; 172:337-42.
7. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non- small-cell lung carcinoma. N Engl J Med 1993;329:690-4.
8. Ramani P, Lu Qi-L. Expression of bcl-2 gene product in neuroblastoma. J Pathol 1994;172:273-8.
9. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994; 54:6-8.
10. Ben-Ezzra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the bcl-2 protein. Am J Pathol 1994;145:1036-40.
11. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP. Human p53 gene localized to short arm of chromosome 17. Nature 1986;319:783-4.
12. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 352:345-7.
13. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992;89: 4495-9.
14. Lane DP. A death in the life of p53. Nature 1993;362:786-7.
15. Tumors of neural tissue. In: Lever WF, Schaumberg-Lever G, eds. Histopathology of the skin. Philadelphia: JB Lippincott, 1990:749-51.
16. Tungekar MF, Gatter KC, Dunnill MS, Mason DY. Ki67 immunostaining and survival in operable lung cancer. Histopathology 1991;19:545-50.
17. Lohmann D, Puytz B, Reich U, Bohm J, Prauer H, Hofler H. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am J Pathol 1993;142:907-15.
18. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675-9.
19. Brambilla E, Gazzeri S, Moro D, et al. Immunohistochemical study of p53 in human lung carcinomas. Am J Pathol 1993;143:199-210.
20. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? J Pathol 1992;166:329-30.
21. Battifora H. P53 immunohistochemistry: a word of caution. Hum Pathol 1994;25:435-7.
22. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994;54:3131-5.
23. Boise LH, Gonzalez-Garcia M, Postema CE, et al. Bcl-x, a bcl-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993;74:597-8.
24. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
25. Evan GI, Wyllie AH, Gilbert CS, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell 1992;69:119-28.